Lung Cancer
Conference Coverage
Response to preop immunotherapy predicts survival in early NSCLC
For each 10% increase of residual viable tumor, risk of death was increased 64% and risk of recurrence was increased 71%.
Conference Coverage
Studies confirm survival benefit with postchemoradiotherapy consolidation in NSCLC
The findings show a progression-free survival benefit in patients who underwent concurrent or sequential chemoradiotherapy giving insight to real-...
Conference Coverage
Once daily poziotinib shows efficacy in non–small cell lung cancer
No effective treatments exist for patients with NSCLC with EGFR and HER2 exon 20 mutations, but now a new study shows that poziotinib 16 mg daily...
Conference Coverage
Atezolizumab plus chemotherapy superior to best supportive care in early lung cancer
Interim DFS analysis shows that relapse was higher among patients receiving best supportive care, compared with patients who received atezolizumab...
Conference Coverage
Study supports chemotherapy with immunotherapy for some never-smokers with lung cancer
Although patients with PD-L1 expression below 50% derive clear benefit from combination versus single-agent therapy, treatment selection overall...
Conference Coverage
First-line bevacizumab-osimertinib disappoint in EGFR-mutant NSCLC
The combination provided no added progression-free survival benefit over osimertinib monotherapy for EGFR-mutated nonsquamous NSCLC, but raised...
Conference Coverage
Datopotamab deruxtecan for advanced NSCLC encouraging so far
The ongoing TROPION-PanTumor01 clinical trial shows an overall response rate of 35% for patients with advanced or metastatic NSCLC.
Conference Coverage
Nivo/ipi combo now ‘standard of care’ in mesothelioma
After 3 years, 23% of patients who received combination immunotherapy were still alive, in comparison with 15% of patients in the chemotherapy arm...
Conference Coverage
Most community-based oncologists skip biomarker testing
Survey shows that 48% of community clinicians use biomarker testing to guide treatment decisions, compared with 73% of academic clinicians.
Latest News
Flurry of cancer drug endorsements from EU panel
Approvals include pralsetinib for non-small cell lung cancer, ripretinib for advanced gastrointestinal stromal tumor, and zanubrutinib for...
Latest News
FDA approves first oral drug for NSCLC with EGFR Exon 20 insertion
Mobocertinib is the first oral tyrosine kinase inhibitor for patients with metastatic non–small cell lung cancer who have an EGFR Exon 20...